Skip Nav Destination
Issues
1 September 2019
-
Cover Image
Cover Image
ABOUT THE COVER
In their quest to identify novel targets preferentially expressed on tumors, Merlino and colleagues identified CD205 in multiple cancer models, including breast cancer. In this photomicrograph, the level of CD205 is revealed via immunohistochemistry of breast cancer tissue at 40× magnification. Their first-in-class antibody-drug conjugate was most effective in treating cell line xenografts and patient-derived xenografts of triple-negative breast cancer. Read the whole story on page 1533. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1535-7163
EISSN 1538-8514
Highlights
Review
Small Molecule Therapeutics
Structural and Functional Analyses of an Allosteric EYA2 Phosphatase Inhibitor That Has On-Target Effects in Human Lung Cancer Cells
Jothi Anantharajan; Hengbo Zhou; Lingdi Zhang; Taylor Hotz; Melanie Y. Vincent; Melanie A. Blevins; Anna E. Jansson; John Wee Liang Kuan; Elizabeth Yihui Ng; Yee Khoon Yeo; Nithya Baburajendran; Grace Lin; Alvin W. Hung; Joma Joy; Samarjit Patnaik; Juan Marugan; Pratyaydipta Rudra; Debashis Ghosh; Jeffrey Hill; Thomas H. Keller; Rui Zhao; Heide L. Ford; CongBao Kang
Author Choice
Encapsulation of Temozolomide in a Calixarene Nanocapsule Improves Its Stability and Enhances Its Therapeutic Efficacy against Glioblastoma
Alexander Renziehausen; Antonis D. Tsiailanis; Richard Perryman; Evgenios K. Stylos; Christos Chatzigiannis; Kevin O'Neill; Timothy Crook; Andreas G. Tzakos; Nelofer Syed
Phenotype-Based Screens with Conformation-Specific Inhibitors Reveal p38 Gamma and Delta as Targets for HCC Polypharmacology
Jia Xin Yu; Amanda J. Craig; Mary E. Duffy; Carlos Villacorta-Martin; Verónica Miguela; Marina Ruiz de Galarreta; Alexander P. Scopton; Lisa Silber; Andres Y. Maldonado; Alexander Rialdi; Ernesto Guccione; Amaia Lujambio; Augusto Villanueva; Arvin C. Dar
Large Molecule Therapeutics
Author Choice
MEN1309/OBT076, a First-In-Class Antibody–Drug Conjugate Targeting CD205 in Solid Tumors
Giuseppe Merlino; Alessio Fiascarelli; Mario Bigioni; Alessandro Bressan; Corrado Carrisi; Daniela Bellarosa; Massimiliano Salerno; Rossana Bugianesi; Rosanna Manno; Cristina Bernadó Morales; Joaquin Arribas; Arnima Bisht; Angelo Kaplan; Robert Boyd; Uyen T. Do; Sudha Swaminathan; Nickolas Attanasio; San Lin Lou; Rachel L. Dusek; James E. Ackroyd; Phuoc Huy Pham; Rahel Awdew; Dee Aud; Michael Trang; Carmel M. Lynch; Jonathan Terrett; Keith E. Wilson; Christian Rohlff; Stefano Manzini; Andrea Pellacani; Monica Binaschi
Anti-GPRC5D/CD3 Bispecific T-Cell–Redirecting Antibody for the Treatment of Multiple Myeloma
Tatsushi Kodama; Yu Kochi; Waka Nakai; Hideaki Mizuno; Takeshi Baba; Kiyoshi Habu; Noriaki Sawada; Hiroyuki Tsunoda; Takahiro Shima; Kohta Miyawaki; Yoshikane Kikushige; Yasuo Mori; Toshihiro Miyamoto; Takahiro Maeda; Koichi Akashi
Cancer Biology and Translational Studies
Mechanisms of Resistance to EGFR Inhibition Reveal Metabolic Vulnerabilities in Human GBM
Andrew McKinney; Olle R. Lindberg; Jane R. Engler; Katharine Y. Chen; Anupam Kumar; Henry Gong; Kan V. Lu; Erin F. Simonds; Timothy F. Cloughesy; Linda M. Liau; Michael Prados; Andrew W. Bollen; Mitchel S. Berger; Joseph T.C. Shieh; C. David James; Theodore P. Nicolaides; William H. Yong; Albert Lai; Monika E. Hegi; William A. Weiss; Joanna J. Phillips
Author Choice
Glutaminase Activity of L-Asparaginase Contributes to Durable Preclinical Activity against Acute Lymphoblastic Leukemia
Wai-Kin Chan; Thomas D. Horvath; Lin Tan; Todd Link; Karine G. Harutyunyan; Michael A. Pontikos; Andriy Anishkin; Di Du; Leona A. Martin; Eric Yin; Susan B. Rempe; Sergei Sukharev; Marina Konopleva; John N. Weinstein; Philip L. Lorenzi
Monomer Preference of EGFR Tyrosine Kinase Inhibitors Influences the Synergistic Efficacy of Combination Therapy with Cetuximab
Ayano Oashi; Hiroyuki Yasuda; Keigo Kobayashi; Tetsuo Tani; Junko Hamamoto; Keita Masuzawa; Tadashi Manabe; Hideki Terai; Shinnosuke Ikemura; Ichiro Kawada; Katsuhiko Naoki; Kenzo Soejima
Antileukemia Effects of Notch-Mediated Inhibition of Oncogenic PLK1 in B-Cell Acute Lymphoblastic Leukemia
Sankaranarayanan Kannan; Marisa J.L. Aitken; Shelley M. Herbrich; Leonard S. Golfman; Mandy G. Hall; Duncan H. Mak; Jared K. Burks; Guangchun Song; Marina Konopleva; Charles G. Mullighan; Joya Chandra; Patrick A. Zweidler-McKay
Author Choice
Analysis of the Genomic Landscape in ALK+ NSCLC Patients Identifies Novel Aberrations Associated with Clinical Outcomes
Mathilde Couëtoux du Tertre; Maud Marques; Lise Tremblay; Nicole Bouchard; Razvan Diaconescu; Normand Blais; Christian Couture; Vincent Pelsser; Hangjun Wang; Valerie Higenell; Luisa Izzi; Karen Gambaro; Cyrla Hoffert; Archana Srivastava; Alan Spatz; Caroline Rousseau; Suzan McNamara; Victor Cohen; Gerald Batist; Jason Agulnik
Aggressive Progression in Glioblastoma Cells through Potentiated Activation of Integrin α5β1 by the Tenascin-C–Derived Peptide TNIIIA2
Motomichi Fujita; Tetsuya Yamamoto; Takuya Iyoda; Tatsuya Fujisawa; Manabu Sasada; Reo Nagai; Chikako Kudo; Kazuki Otsuka; Sadahiro Kamiya; Hiroaki Kodama; Fumio Fukai
Models and Technologies
Editor’s Note
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds